Dupilumab maintains its effectiveness up to five years in patients with eczema: Study
For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8% of patients, according to a study published online Aug. 7 in JAMA Dermatology.
Aug 12, 2024
0
0